Out-of-Pocket Spending for COVID-19 Hospitalizations in 2020 - Chua, Kao-Ping; Conti, Rena M.; Becker, Nora V. (medRxiv, 2021)
IMPORTANCE Many insurers waived cost-sharing for COVID-19 hospitalizations during 2020. Nonetheless, patients may have been billed if their plans did not implement waivers or if waivers did not capture all hospitalization-related care, including clinician services. Assessing out-of-pocket spending for COVID-19 hospitalizations in 2020 could demonstrate the financial burden patients may face if insurers allow waivers to expire, as many chose to do during early 2021.OBJECTIVE To estimate out-of-pocket spending for COVID-19 hospitalizations in 2020DESIGN Cross-sectional analysisSETTING IQVIA PharMetrics® Plus for Academics Database, a national claims databasePARTICIPANTS COVID-19 hospitalizations for privately insured and Medicare Advantage patients during March-September 2020MAIN OUTCOMES/MEASURES Mean total out-of-pocket spending, defined as the sum of out-of-pocket spending for facility services billed by hospitals (e.g., accommodation charges) and for professional/ancillary services billed by clinicians and ancillary providers (e.g., clinician inpatient evaluation and management, ambulance transport)RESULTS Analyses included 4,075 hospitalizations. Of the 1,377 hospitalizations for privately insured patients and the 2,698 hospitalizations for Medicare Advantage patients, 981 (71.2%) and 1,324 (49.1%) had out-of-pocket spending for facility services, professional/ancillary services, or both. Among these hospitalizations, mean (SD) total out-of-pocket spending was 788 (1,411) and 277 (363). In contrast, 63 (4.6%) and 36 (1.3%) hospitalizations had out-of-pocket spending for facility services. Among these hospitalizations, mean total out-of-pocket spending was 3,840 (3,186) and 1,536 (1,402). Total out-of-pocket spending exceeded 4,000 for 2.5% of privately insured hospitalizations, compared with 0.2% of Medicare Advantage hospitalizations.CONCLUSIONS Few COVID-19 hospitalizations in this study had out-of-pocket spending for facility services, suggesting most were covered by insurers with cost-sharing waivers. However, many hospitalizations had out-of-pocket spending for professional/ancillary services. Overall, 7 in 10 privately insured hospitalizations and half of Medicare Advantage hospitalizations had any out-of-pocket spending. Findings suggest insurer cost-sharing waivers may not cover all hospitalization-related care. Moreover, high cost-sharing for some hospitalizations suggests out-of-pocket burden could be substantial if waivers expire, particularly for privately insured patients. Rather than rely on voluntary insurer actions to mitigate this burden, federal policymakers should consider mandating insurers to waive cost-sharing for all COVID-19 hospitalization-related care throughout the pandemic.Question How much were patients billed for COVID-19 hospitalizations in 2020?Findings Of 1,377 and 2,698 COVID-19 hospitalizations for privately insured and Medicare Advantage patients, 71.2% and 49.1% had cost-sharing for facility services billed by hospitals, services billed by clinicians or ancillary providers, or both. Among these hospitalizations, mean out-of-pocket spending was 788 and 277. 4.6% and 1.3% had cost-sharing for facility services; among these hospitalizations, mean out-of-pocket spending was 3,840 and 1,536.Meaning Insurer cost-sharing waivers for COVID-19 hospitalizations may not cover all hospitalization-related care. Patient out-of-pocket burden could be substantial if insurers allow waivers to expire.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for purchasing IQVIA data was partially provided by the Susan B. Meister Child Health Evaluation and Research Center at the University of Michigan Medical School. Dr. Chua is supported by a career development award from the National Institute on Drug Abuse (grant number 1K08DA048110-01). The funders played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Because data were de-identified, the Institutional Review Board of the University of Michigan Medical School exempted analyses from human subjects review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIQVIA data are proprietary and cannot be shared